Background: It is uncertain whether deterioration after acute ischemic stroke is neurological and/or systemic (somatic) in origin. Methods: 442 consecutive patients admitted with first-ever ischemic stroke (FIS) were assessed by the Unified Neurological Stroke Scale (UNSS) at admission, on hospitalization days 1, 2 and 3 and before discharge. Results: Among 71/442 (16.1%) patients deteriorated during hospitalization, the worsening from stroke onset was early (≤72 h) in 67 (94.4%) of them. The majority (57/71, 80.3%) had CT-confirmed cerebral causes and 14/71 (19.7%) had systemic causes. The causes of late deterioration were exclusively systemic. In the logistic regression analysis the initial mean UNSS score was the only significant independent predictor of stroke deterioration (p < 0.0001). Conclusions: Early clinical deterioration in FIS patients results from infarct-inherent mechanisms while late stroke deterioration is due primarily to systemic factors. An initially severe neurological deficit might predict further decline.

Keywords:
First-ever ischemic stroke, Stroke deterioration, infarct-inherent mechanisms
1.
Castillo J: Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment. Cerebrovasc Dis 1999;9(suppl 3):1–8.
2.
Britton M, Roden A: Progression of stroke after arrival at hospital. Stroke 1985;16:629–632.
3.
Davalos A, Cendra E, Teruel J, Martinez M, Genis D: Deteriorating ischemic stroke: risk factors and prognosis. Neurology 1990;40:1865–1869.
4.
Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS: Effect of blood pressure and diabetes on stroke in progression. Lancet 1994;344:156–159.
5.
Toni D, Fioreli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C, Pozzilli C, Fieschi C: Progressing in neurological deficit secondary to acute ischemic stroke. Arch Neurol 1995;52:670–675.
6.
Castillo J, Davalos A, Noya M: Progression of ischaemic stroke and excitotoxic amino acids. Lancet 1997;349:79–83.
7.
Davalos A, Castillo J, Pumar JM, Noya M: Body temperature and fibrinogen are related to early neurological deterioration in acute ischemic stroke. Cerebrovasc Dis 1997;7:64–69.
8.
Yamamoto H, Bogousslavsky J, van Melle G: Different predictors of neurological worsening in different causes of stroke. Arch Neurol 1998;55:481–486.
9.
Roberts JK, Mohr JP: Stroke-in-evolution; in Welch KMA, Caplan LR, Reis DJ, Siesjo, Weir B (eds): Primer on cerebrovascular disease. San Diego, Academic Press, 1997, pp 765–767.
10.
Hachinski V, Norris JW: The Acute Stroke. Philadelphia, Davis, 1985, pp 123–140.
11.
Davalos A, Castillo J: Progressing stroke; in Fisher M, Bogousslavsky J (eds): Current Review of Cerebrovascular Disease, ed 3. Philadelphia, Current Medicine, 1999, pp 149–160.
12.
Davalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J, for the ECASS Group: Neurological deterioration in acute ischemic stroke: Potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke 1999;30:2631–2636.
13.
Davalos A, Castillo J: Potential mechanisms of worsening. Cerebrovasc Dis 1997;7(suppl 5):19–24.
14.
Orgogozo JM, Asplund K, Boysen J: A unified form for neurological scoring of hemispheric stroke with motor impairment. Stroke 1992;23:1678–1679.
15.
Carter AB: Ingravescent cerebral infarction. Q J Med 1960;29:611.
16.
Millikan CH, McDowell F, Easton JD: Progressing stroke; in Millikan CH, McDowell F, Easton JD (eds): Stroke. Philadelphia, Lea & Febiger, 1987, pp 117–130.
17.
Castillo J, Davalos A, Noya M: Timing for fever-related brain damage in acute ischemic stroke. Stroke 1998;29:2455–2460.
18.
Lidenstrom E, Boysen G, Christiansen LW, Hansen R, Nielsen BW: Reliability of Scandinavian Stroke Scale. Cerebrovasc Dis 1991;1:103–107.
19.
Castillo J, Martinez F, Leira R, Prieto JM, Lema M, Noya M: Mortality and morbidity of acute cerebral infarction related to temperature and basal analytic parameters. Cerebrovasc Dis 1994;4:66–71.
20.
Naveiro J, Castillo J, Suarez P, Aldrey JM, Lema M, Noya M: Time for cerebral damage due to hyperglycemia in acute ischemia (in Spanish). Rev Neurol 1998;26:790–793.
21.
Treves TA, Karepov VG, Aronovich BD, Gorbulev AY, Bornstein NM, Korczyn AD: Interrater agreement in evaluation of stroke patients with the unified neurological stroke scale. Stroke 1994;25:1263–1264.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.